See the pharma and biotech signals investors should be watching now

Pharma and biotech markets are being shaped by more than headline deal activity. Regulatory change, China’s expanding pipeline, emerging science, pricing pressure, AI-enabled scouting, and shifting buyer appetite are all changing how opportunities and risks are assessed.

Download Article Spotlight: What Investors Need to Know Across Pharma and Biotech for a curated view of the developments from Scrip, Pink Sheet, and In Vivo.

First Name *

Last Name *

Company *

Job Title *

Business Email Address *

Country *

Business Phone

How Can We Help

fieldlabel

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.
サイトラインより、関連する製品・サービス・コンテンツに関する情報をお届けする場合があります。配信停止や受信内容の管理をご希望の場合は、プリファレンスセンターをご利用ください。

ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。

What you’ll find

Inside the eBook, you’ll find analysis covering:

Why biotech momentum is returning, but on different terms than the 2020–2021 market
How the $500bn patent cliff is increasing pressure for pharma to source external growth
Why China-originated assets now account for roughly 30% of the global pipeline
Where first-in-class oncology mechanisms, including pan-RAS, pan-KRAS and synthetic lethality, are creating new areas to watch
How circular RNA and in vivo CAR-T are moving from platform promise to strategic interest
What EU pharma reform, FDA staffing pressure and pricing reform could mean for asset risk
How AI-enabled scouting is changing how under-the-radar innovation is found

Why Download?

Not every pharma and biotech headline is worth acting on

For financial services professionals, the challenge is knowing which developments could shift market confidence, asset risk, valuation assumptions or deal activity.

This eBook brings together independent reporting and expert analysis on the signals that matter now, including biotech deal momentum, China’s role in the global pipeline, first-in-class oncology, circular RNA, in vivo CAR-T, regulatory reform, and AI-enabled innovation scouting.

Built for financial services professionals tracking pharma and biotech

Whether you are building a market view, screening opportunities, monitoring portfolio exposure, preparing diligence questions or tracking regulatory and clinical momentum, News & Insights helps you stay closer to the developments shaping pharma and biotech.

Scrip, Pink Sheet and In Vivo give you access to independent reporting, expert commentary and market context across the stories that can influence investment thinking.

Stay closer to the stories that could move pharma and biotech markets

Download the eBook to see how we help financial services professionals track the regulatory, clinical, commercial, and dealmaking developments shaping pharma and biotech.

Download the eBook